Cargando…

Environmental triggers of dermatomyositis: a narrative review

Dermatomyositis (DM) is an autoimmune disease that affects the skin, lungs, and muscle. Although the pathogenesis of DM is not completely understood, several environmental triggers have been linked to DM onset or flare. This article specifically examines the effects of herbal supplements, drugs, inf...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bax, Christina E., Maddukuri, Spandana, Ravishankar, Adarsh, Pappas-Taffer, Lisa, Werth, Victoria P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Review Article on Rheumatologic Skin Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8033368/ https://www.ncbi.nlm.nih.gov/pubmed/33842655 http://dx.doi.org/10.21037/atm-20-3719

Ejemplares similares

AB017. Increased dendritic cells and IFN-beta and MxA protein expression in spongiotic dermatitis differentiates dermatomyositis from eczema
por: Zeidi, Majid, et al.
Publicado: (2021)

AB014. Developing classification criteria for skin-predominant dermatomyositis: assessing the methodology of the prospective validation study
por: Concha, Josef Symon S., et al.
Publicado: (2021)

AB018. Myeloid dendritic cells (mDCs) are major producers of interferon-beta in dermatomyositis and increased numbers of mDCs are found in hydroxychloroquine nonresponders
por: Chen, Kristen L., et al.
Publicado: (2021)

Dermatomyositis and malignancy: should all patients with dermatomyositis undergo malignancy screening?
por: Khanna, Urmi, et al.
Publicado: (2021)

The CLASI, a validated tool for the evaluation of skin disease in lupus erythematosus: a narrative review
por: Chakka, Srita, et al.
Publicado: (2021)

AB015. Skin disease activity and autoantibody phenotype are major determinants of blood interferon signatures in dermatomyositis
por: Tabata, Mika, et al.
Publicado: (2021)

AB019. Response to tofacitinib in a case of refractory TIF-1 positive amyopathic dermatomyositis with arthritis
por: Jasmine, Sion Ward, et al.
Publicado: (2021)

AB004. Evaluating differences in meaningful change in disease activity between different races and clinical subtypes affected by cutaneous lupus erythematosus
por: Chakka, Srita, et al.
Publicado: (2021)

Why rheumatologic skin disease?
por: Sontheimer, Richard D., et al.
Publicado: (2021)

AB021. Comparing the performance of two interferon-gamma release assays in autoimmune skin disease patients: a prospective study
por: Krain, Rebecca L., et al.
Publicado: (2021)

AB005. Assessing meaningful changes in disease activity as clinical trial clinical efficacy measures for cutaneous lupus erythematosus
por: Chakka, Srita, et al.
Publicado: (2021)

AB003. Increased CD69+ tissue-resident memory T cells and STAT3 expression in cutaneous lupus erythematosus patients recalcitrant to antimalarials
por: Zeidi, Majid, et al.
Publicado: (2021)

AB016. A double-blind, placebo-controlled, phase 2 trial of a novel toll-like receptor 7/8/9 antagonist (IMO-8400) in dermatomyositis
por: Kim, Yoo Jung, et al.
Publicado: (2021)

Covert clues: the non-hallmark cutaneous manifestations of dermatomyositis
por: Castillo, Rochelle L., et al.
Publicado: (2021)

Dermatomyositis autoantibodies: how can we maximize utility?
por: Hodgkinson, Luqman Mushila, et al.
Publicado: (2021)

Polishing the crystal ball: mining multi-omics data in dermatomyositis
por: Castillo, Rochelle L., et al.
Publicado: (2021)

Herbal supplement Spirulina stimulates inflammatory cytokine production in patients with dermatomyositis in vitro
por: Bax, Christina E., et al.
Publicado: (2023)

AB008. Utility of repeat latent tuberculosis testing in patients with immune-mediated diseases taking biologics
por: Khanna, Urmi, et al.
Publicado: (2021)

AB020. A case report on cutaneous necrotizing vasculitis treated with colchicine in a Filipino adult male
por: Cruz, Luisa Marie S., et al.
Publicado: (2021)

AB025. Acute arthritis with dermatitis: a case of multicentric reticulohistiocytosis
por: Niaki, Omid Zahedi, et al.
Publicado: (2021)

AB009. Successful treatment of severe systemic lupus erythematosus and psoriasis with IL-17A inhibition
por: Robinett, Danielle M., et al.
Publicado: (2021)

AB006. A modular analysis approach to studying gene expression in cutaneous lupus erythematosus
por: Zhu, Jane, et al.
Publicado: (2021)

AB013. CXCL4-DNA immune complexes drive inflammation in systemic sclerosis by amplifying TLR9-mediated interferon-α production
por: Lee, Ernest Y., et al.
Publicado: (2021)

AB011. A Gottron’s papule mimicker: an unusual presentation of porokeratosis plantaris palmaris et disseminata
por: Schoenberg, Elizabeth, et al.
Publicado: (2021)

AB001. Understanding transcriptional connections of chronic cutaneous lupus erythematosus between humans and animal models
por: Banovic, Frane, et al.
Publicado: (2021)

AB012. Clinical and demographic features of morphea patients with mucocutaneous involvement: a cross sectional study from the morphea of adults and children (MAC cohort)
por: Prasad, Smriti, et al.
Publicado: (2021)

AB002. Quality of life is inversely related to income in patients with cutaneous lupus
por: Prasad, Smriti, et al.
Publicado: (2021)

AB024. A case of bullous systemic lupus erythematosus confined to the oral mucosa
por: Strunck, Jennifer, et al.
Publicado: (2021)

AB007. Worse skin disease severity may distinguish patients who progress from cutaneous lupus erythematous to systemic lupus erythematous
por: Walocko, Frances, et al.
Publicado: (2021)

AB010. Keloidal scleroderma with isolated intertriginous involvement
por: Balakrishnan, Vijay, et al.
Publicado: (2021)

AB022. Biologics and vaccination: relationship of influenza, pneumonia and zoster
por: Patel, Deep, et al.
Publicado: (2021)

AB023. An atypical clinical presentation of alopecia in two patients with systemic lupus erythematosus
por: Lerman, Irina, et al.
Publicado: (2021)

A Case of Dermatomyositis Causing Cryptogenic Organizing Pneumonia
por: Miskoff, Jeffrey A, et al.
Publicado: (2019)

Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo effects of Lenabasum(TM)
por: Maddukuri, Spandana, et al.
Publicado: (2022)

Correction to: Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo efects of Lenabasum(TM)
por: Maddukuri, Spandana, et al.
Publicado: (2022)

Anti-TIF1gamma Antibody-Positive Dermatomyositis Associated with Myelodysplastic Syndrome: Response to Treatment
por: Lerman, Irina, et al.
Publicado: (2019)

Systemic sclerosis (scleroderma): remaining challenges
por: Connolly, Mary Karin
Publicado: (2021)

Evaluating safety and compatibility of anti-tumor necrosis factor therapy in patients with connective tissue disorders
por: Said, Jordan T., et al.
Publicado: (2021)

Advances in cutaneous vasculitis research and clinical care
por: Caplan, Avrom, et al.
Publicado: (2021)

Role of biomarkers in the diagnosis and prognosis of patients with cutaneous lupus erythematosus
por: Zhu, Jane L., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hmekkhru57dpb2nptas72vfalo